Muruganantham Bharathi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Muruganantham Bharathi has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Bhagavathi Sundaram Sivamaruthi
Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand
7 shared publications - Chaiyavat Chaiyasut
Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand
7 shared publications - Periyanaina Kesika
Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand
6 shared publications Palanisamy Arulselvan
Department of Chemistry, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, 602 105, India
4 shared publications- Sridhar Muthusami
Department of Biochemistry, Karpagam Academy of Higher Education, Coimbatore 641 021, Tamil Nadu, India
4 shared publications Rangaraj Kaviyaprabha
Centre for Bioinformatics, Department of Biochemistry, Karpagam Academy of Higher Education, Coimbatore, TamilNadu, 641021, India
3 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (11) , 1236
Reproducibility of Transcriptomic Signatures and Candidate Genes in Human Intervertebral Disc Degeneration: A Discovery–Validation Re-Analysis of Public Datasets
Purpose: Integrative analyses of public transcriptomic datasets are widely used to nominate hub genes and therapeutic targets in intervertebral disc degeneration (IVDD), but whether such candidates replicate across datasets is rarely tested. We assessed the reproducibility of gene- and pathway-level signatures of IVDD using a discovery–validation design. Methods:Six Gene Expression Omnibus (GEO) series used in an overlap-and-network pipeline (four degeneration-versus-control comparisons and two cell-type or intervention contrasts) were re-analysed dataset by dataset (limma or DESeq2, with design adjustment where needed). Thirty-three candidate genes from that pipeline were audited, and a weighted Stouffer meta-analysis of the four discovery datasets was tested for replication in three independent validation cohorts (GSE70362, 48 samples from 18 donors; the non-overlapping samples of GSE23130; GSE34095). We also quantified genome-wide agreement between datasets, checked sample uniqueness, performed pre-ranked gene set enrichment analysis (Hallmark and Reactome) and analysed a combined protein–protein interaction network. Results:Samples 1–15 of GSE23130 were the specimens of GSE15227, and 23 PubMed Central articles cite both accessions. Genome-wide agreement between degeneration datasets was negligible (Spearman ρ −0.13 to 0.13). Of 1252 genes significant in the discovery meta-analysis, 49% changed in the same direction in validation (binomial p = 0.78); 15 replicated and two remained robust to leave-one-dataset-out analysis. None of the 33 candidates replicated robustly; ACAN, COL9A3 and COL11A2 changed significantly in the opposite direction in validation, and the apparent downregulation of MMP3 and MMP9 arose only from non-degeneration contrasts. A reproducible overlap step selected 14 mainly interferon-related genes driven by these contrasts. At the pathway level, E2F target and G2-M checkpoint (proliferation) gene sets were enriched in both meta-analyses and had positive enrichment scores in all nine datasets, whereas inflammatory and TNF-α/NF-κB signatures did not replicate. Conclusions:Gene-level IVDD signatures derived from small public datasets are not reproducible, and overlap-based hub genes should not be presented as therapeutic targets without independent validation. Within the datasets examined, a cell proliferation programme was the most consistent pathway-level signal; whether it is a feature of disc degeneration requires experimental validation. We provide a checklist for future secondary analyses of IVDD transcriptomes.
- 16 November 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (11) , 1236
Open AccessReproducibility of Transcriptomic Signatures and Candidate Genes in Human Intervertebral Disc Degeneration: A Discovery–Validation Re-Analysis of Public Datasets
Purpose: Integrative analyses of public transcriptomic datasets are widely used to nominate hub genes and therapeutic targets in intervertebral disc degeneration (IVDD), but whether such candidates replicate across datasets is rarely tested. We assessed the reproducibility of gene- and pathway-level signatures of IVDD using a discovery–validation design. Methods:Six Gene Expression Omnibus (GEO) series used in an overlap-and-network pipeline (four degeneration-versus-control comparisons and two cell-type or intervention contrasts) were re-analysed dataset by dataset (limma or DESeq2, with design adjustment where needed). Thirty-three candidate genes from that pipeline were audited, and a weighted Stouffer meta-analysis of the four discovery datasets was tested for replication in three independent validation cohorts (GSE70362, 48 samples from 18 donors; the non-overlapping samples of GSE23130; GSE34095). We also quantified genome-wide agreement between datasets, checked sample uniqueness, performed pre-ranked gene set enrichment analysis (Hallmark and Reactome) and analysed a combined protein–protein interaction network. Results:Samples 1–15 of GSE23130 were the specimens of GSE15227, and 23 PubMed Central articles cite both accessions. Genome-wide agreement between degeneration datasets was negligible (Spearman ρ −0.13 to 0.13). Of 1252 genes significant in the discovery meta-analysis, 49% changed in the same direction in validation (binomial p = 0.78); 15 replicated and two remained robust to leave-one-dataset-out analysis. None of the 33 candidates replicated robustly; ACAN, COL9A3 and COL11A2 changed significantly in the opposite direction in validation, and the apparent downregulation of MMP3 and MMP9 arose only from non-degeneration contrasts. A reproducible overlap step selected 14 mainly interferon-related genes driven by these contrasts. At the pathway level, E2F target and G2-M checkpoint (proliferation) gene sets were enriched in both meta-analyses and had positive enrichment scores in all nine datasets, whereas inflammatory and TNF-α/NF-κB signatures did not replicate. Conclusions:Gene-level IVDD signatures derived from small public datasets are not reproducible, and overlap-based hub genes should not be presented as therapeutic targets without independent validation. Within the datasets examined, a cell proliferation programme was the most consistent pathway-level signal; whether it is a feature of disc degeneration requires experimental validation. We provide a checklist for future secondary analyses of IVDD transcriptomes.
- Open Access
- 13 November 2026
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 38 (11) , 2947-2967
Experimental and Theoretical Insights into Structural, Spectroscopy, DFT and Biological Activity of 5-Fluorouracil Thiourea Cocrystal
A cocrystal of the anticancer drug 5-fluorouracil with thiourea (5FUTU) was synthesized and single crystal was grown by slow solvent evaporation. Single-crystal X-ray diffraction (SCXRD) established the unit cell parameters and powder X-ray diffraction (PXRD) confirmed the formation and phase purity of the cocrystalline phase. Hirshfeld surface analysis and the associated two-dimensional fingerprint plots were used to identify the intermolecular interactions governing crystal packing and to quantify their relative contributions. The functional groups in 5FUTU were characterized by Fourier-transform infrared (FTIR) spectroscopy and its electronic absorption behaviour was examined by UV-Vis spectroscopy. Density functional theory (DFT) calculations were performed to support the experimentally determined crystal structure and to elucidate the spectroscopic and electronic properties of the cocrystal. The calculations included frontier molecular orbital (HOMO-LUMO) energies, natural and Mulliken population analyses, Fukui functions to gain further insight into its electronic distribution, chemical reactivity and stability. The biological potential of 5FUTU was evaluated by molecular docking and an in vitro MTT cytotoxicity assay. Molecular docking revealed favourable binding of 5FUTU to glycogen synthase kinase-3β (GSK-3β), with a binding energy of -6.6 kcal/mol. The MTT assay showed cytotoxic activity against MDA-MB-231 breast cancer cells, with an IC50 of 46.7 µM. Pharmacokinetic analysis assessed its drug-likeness and support further investigation of 5FUTU in structure-based drug design for breast cancer therapy.
- 13 November 2026
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 38 (11) , 2947-2967
Open AccessExperimental and Theoretical Insights into Structural, Spectroscopy, DFT and Biological Activity of 5-Fluorouracil Thiourea Cocrystal
A cocrystal of the anticancer drug 5-fluorouracil with thiourea (5FUTU) was synthesized and single crystal was grown by slow solvent evaporation. Single-crystal X-ray diffraction (SCXRD) established the unit cell parameters and powder X-ray diffraction (PXRD) confirmed the formation and phase purity of the cocrystalline phase. Hirshfeld surface analysis and the associated two-dimensional fingerprint plots were used to identify the intermolecular interactions governing crystal packing and to quantify their relative contributions. The functional groups in 5FUTU were characterized by Fourier-transform infrared (FTIR) spectroscopy and its electronic absorption behaviour was examined by UV-Vis spectroscopy. Density functional theory (DFT) calculations were performed to support the experimentally determined crystal structure and to elucidate the spectroscopic and electronic properties of the cocrystal. The calculations included frontier molecular orbital (HOMO-LUMO) energies, natural and Mulliken population analyses, Fukui functions to gain further insight into its electronic distribution, chemical reactivity and stability. The biological potential of 5FUTU was evaluated by molecular docking and an in vitro MTT cytotoxicity assay. Molecular docking revealed favourable binding of 5FUTU to glycogen synthase kinase-3β (GSK-3β), with a binding energy of -6.6 kcal/mol. The MTT assay showed cytotoxic activity against MDA-MB-231 breast cancer cells, with an IC50 of 46.7 µM. Pharmacokinetic analysis assessed its drug-likeness and support further investigation of 5FUTU in structure-based drug design for breast cancer therapy.
- 23 October 2026
- Published by Springer Nature in 3 Biotech
- Vol. 16 (11) , 474
Reciprocal MDK–THRB lipid-oxidation transcriptional programs in MASH-associated hepatocellular carcinoma: a two-cohort human transcriptomic analysis
Purpose Midkine (MDK) and thyroid hormone receptor beta (THRB) have each been implicated separately in metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma (HCC). THRB drives hepatic fatty-acid beta-oxidation (FAO). We tested whether MDK and the THRB-linked FAO program are reciprocally related in human liver tissue. Methods We analyzed two independent human cohorts on different platforms. TCGA-LIHC provided 374 tumor and 50 adjacent non-tumor RNA-seq samples. GSE164760 provided 53 NASH-HCC, 74 NASH, 29 non-tumoral NASH adjacent to HCC, 8 cirrhotic and 6 healthy microarray samples. We quantified MDK, THRB and a curated 21-gene hepatic FAO composite score. Tests included Mann-Whitney, Spearman, Kruskal-Wallis, Jonckheere-Terpstra and genome-wide correlation with Benjamini-Hochberg correction. Results MDK was higher in tumor tissue in both cohorts (TCGA-LIHC p = 1.0 × 10-24, GSE164760 p = 8.1 × 10-13). The FAO composite was correspondingly lower (p = 7.0 × 10-10 and p = 7.1 × 10-6). THRB itself was lower in GSE164760 (p = 3.9 × 10-3) but not in TCGA-LIHC (p = 0.509). MDK correlated negatively with THRB and with the FAO composite in both cohorts. The strongest association was MDK versus FAO composite (rho=-0.45 in each cohort). Within-group analysis showed that the THRB to FAO composite correlation persisted in almost every subgroup. The MDK correlations weakened in three smaller subgroups. Across the five GSE164760 disease states, MDK, THRB and the FAO composite each differed significantly (Kruskal-Wallis p < 10−5) and each followed a significant monotonic trend (Jonckheere-Terpstra one-sided p < = 1.5 × 10-3). Conclusion A reciprocal MDK-high and FAO-low transcriptional signature is reproducible across two independent human cohorts and across the MASH-to-HCC spectrum. These human tissue data support THRB agonism as a candidate therapeutic rationale in MASH-HCC that warrants prospective validation.
- 23 October 2026
- Published by Springer Nature in 3 Biotech
- Vol. 16 (11) , 474
Reciprocal MDK–THRB lipid-oxidation transcriptional programs in MASH-associated hepatocellular carcinoma: a two-cohort human transcriptomic analysis
Purpose Midkine (MDK) and thyroid hormone receptor beta (THRB) have each been implicated separately in metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma (HCC). THRB drives hepatic fatty-acid beta-oxidation (FAO). We tested whether MDK and the THRB-linked FAO program are reciprocally related in human liver tissue. Methods We analyzed two independent human cohorts on different platforms. TCGA-LIHC provided 374 tumor and 50 adjacent non-tumor RNA-seq samples. GSE164760 provided 53 NASH-HCC, 74 NASH, 29 non-tumoral NASH adjacent to HCC, 8 cirrhotic and 6 healthy microarray samples. We quantified MDK, THRB and a curated 21-gene hepatic FAO composite score. Tests included Mann-Whitney, Spearman, Kruskal-Wallis, Jonckheere-Terpstra and genome-wide correlation with Benjamini-Hochberg correction. Results MDK was higher in tumor tissue in both cohorts (TCGA-LIHC p = 1.0 × 10-24, GSE164760 p = 8.1 × 10-13). The FAO composite was correspondingly lower (p = 7.0 × 10-10 and p = 7.1 × 10-6). THRB itself was lower in GSE164760 (p = 3.9 × 10-3) but not in TCGA-LIHC (p = 0.509). MDK correlated negatively with THRB and with the FAO composite in both cohorts. The strongest association was MDK versus FAO composite (rho=-0.45 in each cohort). Within-group analysis showed that the THRB to FAO composite correlation persisted in almost every subgroup. The MDK correlations weakened in three smaller subgroups. Across the five GSE164760 disease states, MDK, THRB and the FAO composite each differed significantly (Kruskal-Wallis p < 10−5) and each followed a significant monotonic trend (Jonckheere-Terpstra one-sided p < = 1.5 × 10-3). Conclusion A reciprocal MDK-high and FAO-low transcriptional signature is reproducible across two independent human cohorts and across the MASH-to-HCC spectrum. These human tissue data support THRB agonism as a candidate therapeutic rationale in MASH-HCC that warrants prospective validation.
- 1 March 2026
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 26 (2) , 1-26
Elucidating the Predominant Role of AEBP1 in Different Types of Cancers with a Focus on Glioblastoma Progression – A Review
Introduction: Glioblastoma multiforme (GBM) is a highly deleterious lesion with an increased recurrence rate even after radiotherapy and chemotherapy. In this context, additional biomarkers are needed to curb chemoresistance. Computational approaches help us process the RNA-seq and identify the Differentially Expressed Genes (DEGs) in tumors and adjacent normal regions to identify the diagnostic and therapeutic biomarkers. Methods and Materials: In this study, we extensively reviewed the role of AEBP1 in different types of cancer, highlighting its significance as a novel target to prevent collagen deposition. Specifically, the underlying mechanisms of AEBP1 in Glioblastoma were analyzed extensively using computational approaches that include Gene Expression Omnibus (GEO), GEPIA to obtain the TCGA-GBM dataset, and Glioma-BioDP to identify the survival rate in the context of AEBP1 expression associated with patients' age. Meanwhile, Tumor Immune Single-cell Hub 2 was implemented to identify the expression of AEBP1 in immunologically lineaged, cancerous, and stromal cells. In addition to that, the miRNA regulation associated with the AEBP1 expression was predicted by implementing NetworkAnalyst, TarBase v8.0, and CancerMIRNome. We identified the DEGs by examining the GSE121723, GSE184643, and GSE14824 datasets with P-values ≤ 0.05 as statistically significant. Furthermore, we predicted and analyzed the highly expressed genes and identified the survival rate, which significantly stated that the overexpression of AEBP1 was associated with decreased survival rates in GBM patients. The Protein-Protein Interaction network was constructed to identify the correlated gene expression. Results and Discussion: We identified 3695, 37001, and 8855 significantly differentially expressed genes (DEGs). The DEGs were filtered by applying a log2 fold-change cut-off of ≥2.0. Finally, 139 common genes were mapped with the identified DEGs (1338 genes) and SDEs (500 genes) estimated from the TCGA-GBM dataset. The analysis revealed that 155 genes are commonly upregulated, and survival analyses were performed that described the AEBP1 significantly reduced the GBM patients' survival rate among other genes. The constructed PPI network and correlated expression analysis associated with the AEBP1 expression revealed that COL6A2 and THBS2 might play a significant role in the GBM stage advancements by depositing collagens in the matrix environment. Also, the miRNA analysis revealed that the hsa-miR-128-3p and hsa-miR-512-3p could be targeted as a miRNA marker gene to prevent the GBM progression associated with the AEBP1 expression. Conclusion: AEBP1 is a multi-cancer drug target, underscoring its diagnostic and prognostic value in different types of cancer preventive medicine. It influences tumor growth, metastasis, and immune evasion in cancers like adrenocortical, oral, breast, bladder, gastric, colon, and ovarian by activating the NF-κB pathway and disrupting tumor suppressors. Our findings additionally identified AEBP1 as a key regulator in glioblastoma (GBM) progression, with its overexpression [log2FC = 8.207; P ≤ 0.05] linked to reduced survival [HR = 2.1; P = 4.9e-05]. Targeting AEBP1 via TGFβs and its receptors could inhibit the collagen-depositing gene COL6A2 and THBS2, a key TME modulator. Further, the hsa-miR-128-3p (AUC = 0.94) could be a potential therapeutic target to prevent the expression of AEBP1. Following an extensive review and in-depth discussion, our investigation presents a potentially promising avenue to develop small drug-like molecules and monoclonal antibodies against AEBP1 expression for ameliorating patient survival rates.
- 1 March 2026
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 26 (2) , 1-26
Elucidating the Predominant Role of AEBP1 in Different Types of Cancers with a Focus on Glioblastoma Progression – A Review
Introduction: Glioblastoma multiforme (GBM) is a highly deleterious lesion with an increased recurrence rate even after radiotherapy and chemotherapy. In this context, additional biomarkers are needed to curb chemoresistance. Computational approaches help us process the RNA-seq and identify the Differentially Expressed Genes (DEGs) in tumors and adjacent normal regions to identify the diagnostic and therapeutic biomarkers. Methods and Materials: In this study, we extensively reviewed the role of AEBP1 in different types of cancer, highlighting its significance as a novel target to prevent collagen deposition. Specifically, the underlying mechanisms of AEBP1 in Glioblastoma were analyzed extensively using computational approaches that include Gene Expression Omnibus (GEO), GEPIA to obtain the TCGA-GBM dataset, and Glioma-BioDP to identify the survival rate in the context of AEBP1 expression associated with patients' age. Meanwhile, Tumor Immune Single-cell Hub 2 was implemented to identify the expression of AEBP1 in immunologically lineaged, cancerous, and stromal cells. In addition to that, the miRNA regulation associated with the AEBP1 expression was predicted by implementing NetworkAnalyst, TarBase v8.0, and CancerMIRNome. We identified the DEGs by examining the GSE121723, GSE184643, and GSE14824 datasets with P-values ≤ 0.05 as statistically significant. Furthermore, we predicted and analyzed the highly expressed genes and identified the survival rate, which significantly stated that the overexpression of AEBP1 was associated with decreased survival rates in GBM patients. The Protein-Protein Interaction network was constructed to identify the correlated gene expression. Results and Discussion: We identified 3695, 37001, and 8855 significantly differentially expressed genes (DEGs). The DEGs were filtered by applying a log2 fold-change cut-off of ≥2.0. Finally, 139 common genes were mapped with the identified DEGs (1338 genes) and SDEs (500 genes) estimated from the TCGA-GBM dataset. The analysis revealed that 155 genes are commonly upregulated, and survival analyses were performed that described the AEBP1 significantly reduced the GBM patients' survival rate among other genes. The constructed PPI network and correlated expression analysis associated with the AEBP1 expression revealed that COL6A2 and THBS2 might play a significant role in the GBM stage advancements by depositing collagens in the matrix environment. Also, the miRNA analysis revealed that the hsa-miR-128-3p and hsa-miR-512-3p could be targeted as a miRNA marker gene to prevent the GBM progression associated with the AEBP1 expression. Conclusion: AEBP1 is a multi-cancer drug target, underscoring its diagnostic and prognostic value in different types of cancer preventive medicine. It influences tumor growth, metastasis, and immune evasion in cancers like adrenocortical, oral, breast, bladder, gastric, colon, and ovarian by activating the NF-κB pathway and disrupting tumor suppressors. Our findings additionally identified AEBP1 as a key regulator in glioblastoma (GBM) progression, with its overexpression [log2FC = 8.207; P ≤ 0.05] linked to reduced survival [HR = 2.1; P = 4.9e-05]. Targeting AEBP1 via TGFβs and its receptors could inhibit the collagen-depositing gene COL6A2 and THBS2, a key TME modulator. Further, the hsa-miR-128-3p (AUC = 0.94) could be a potential therapeutic target to prevent the expression of AEBP1. Following an extensive review and in-depth discussion, our investigation presents a potentially promising avenue to develop small drug-like molecules and monoclonal antibodies against AEBP1 expression for ameliorating patient survival rates.
- 11 October 2025
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 197 (11) , 7552-7580
Inhibitory Effects of Hesperetin and EGCG in the Lung Cancer Progression involves impairment in TOP2A gene expression regulation
Lung cancer (LC) remains the leading cause of death among all cancer-related mortalities. Despite advances in Non-Small Cell Lung Cancer (NSCLC) treatment, rising drug resistance necessitates the development of new therapeutics targeting relevant biomarkers. Understanding resistance mechanisms is key to improving treatment effectiveness and overcoming drug resistance. This study aims to identify crucial biomarkers and evaluate potential drug-like compounds targeting them using both in silico and in vitro analyses. Ten key biomarkers associated with LC—including Assembly Factor for Spindle Microtubules (ASPM), Budding Uninhibited by Benzimidazoles 1 (BUB1), Centromere Protein F (CENPF), DNA Topoisomerase II Alpha (TOP2A), TPX2 Microtubule Nucleation Factor (TPX2), Kinesin Family Member 15 (KIF15), Ubiquitin Conjugating Enzyme E2 C (UBE2C), Marker of Proliferation Ki-67 (MK167), Hyaluronan-Mediated Motility Receptor (HMMR), and Cyclin B2 (CCNB2)—were identified from GEO datasets (GSE4882, GSE40275, GSE22874, GSE166720, GSE7880, GSE1987, GSE45142, GSE162102, GSE63571, and GSE23361) using the GEO2R tool. A molecular docking study involving 18 natural compounds was performed against these top 10 biomarker proteins. The compounds hesperetin (binding affinity [BA] = –10.5 kcal/mol; root mean square deviation [RMSD] = 1.569 Å) and epigallocatechin gallate (EGCG) (BA = –9.4 kcal/mol; RMSD = 0.025 Å) showed strong interactions with the TOP2A protein. To substantiate these findings, the efficacy of hesperetin and EGCG was tested in LC cells. The combination treatment had an IC₅₀ of 78 µg/mL in A549 LC cells and significantly reduced cell proliferation, migration, and TOP2A gene expression, as assessed by MTT assay, wound healing assay, and RT-PCR. The results corroborate the computational predictions and support the utility of EGCG and hesperetin in targeting LC at the cellular level.
- 11 October 2025
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 197 (11) , 7552-7580
Inhibitory Effects of Hesperetin and EGCG in the Lung Cancer Progression involves impairment in TOP2A gene expression regulation
Lung cancer (LC) remains the leading cause of death among all cancer-related mortalities. Despite advances in Non-Small Cell Lung Cancer (NSCLC) treatment, rising drug resistance necessitates the development of new therapeutics targeting relevant biomarkers. Understanding resistance mechanisms is key to improving treatment effectiveness and overcoming drug resistance. This study aims to identify crucial biomarkers and evaluate potential drug-like compounds targeting them using both in silico and in vitro analyses. Ten key biomarkers associated with LC—including Assembly Factor for Spindle Microtubules (ASPM), Budding Uninhibited by Benzimidazoles 1 (BUB1), Centromere Protein F (CENPF), DNA Topoisomerase II Alpha (TOP2A), TPX2 Microtubule Nucleation Factor (TPX2), Kinesin Family Member 15 (KIF15), Ubiquitin Conjugating Enzyme E2 C (UBE2C), Marker of Proliferation Ki-67 (MK167), Hyaluronan-Mediated Motility Receptor (HMMR), and Cyclin B2 (CCNB2)—were identified from GEO datasets (GSE4882, GSE40275, GSE22874, GSE166720, GSE7880, GSE1987, GSE45142, GSE162102, GSE63571, and GSE23361) using the GEO2R tool. A molecular docking study involving 18 natural compounds was performed against these top 10 biomarker proteins. The compounds hesperetin (binding affinity [BA] = –10.5 kcal/mol; root mean square deviation [RMSD] = 1.569 Å) and epigallocatechin gallate (EGCG) (BA = –9.4 kcal/mol; RMSD = 0.025 Å) showed strong interactions with the TOP2A protein. To substantiate these findings, the efficacy of hesperetin and EGCG was tested in LC cells. The combination treatment had an IC₅₀ of 78 µg/mL in A549 LC cells and significantly reduced cell proliferation, migration, and TOP2A gene expression, as assessed by MTT assay, wound healing assay, and RT-PCR. The results corroborate the computational predictions and support the utility of EGCG and hesperetin in targeting LC at the cellular level.
- 18 September 2025
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 25
Synergistic Antiproliferative Effects of EGCG and Myricetin on Cervical Cancer Biomarkers in ME180 and SiHa Cell Lines
Introduction: Identifying potential biomarkers for the detection, diagnosis, and monitoring of cervical cancer (CC) constitutes a key area for future research. Methods: Differentially expressed genes (DEGs) and survival-associated DEGs (SDEGs) were identified using the GEPIA2 database through the TCGA-CESC dataset. The 3D structures of target proteins were predicted using trRosetta and validated via SAVES v6.0. Phytocompounds were retrieved from the PubChem database, and docking studies were performed using AutoDock Vina. The miRNAs regulating HK2 and MAP7 were also predicted by implementing miRNetv2.0 and the CancerMIRNome database. Finally, the anticancer activity of these compounds was validated individually and in combination using the ME180 and SiHa CC cell lines. Results: The present study identified the top five most hazardous novel biomarkers through DEGs (5763) and SDEGs (500) (P-value ≤ 0.05). The phytocompounds EGCG and myricetin interacted with HK2 with binding affinities of -8.3 and -8.1 kcal/mol and RMSDs of 1.369Å and 1.452Å, respectively. Similarly, EGCG (-9.1 kcal/mol) and myricetin (-7.9 kcal/mol), with the RMSD of 1.682Å and 1.148Å, showed strong bonding with the MAP7. EGCG and myricetin treatment synergistically inhibited ME180 (IC50 = 63.49µM) and SiHa (IC50 = 81.54µM) cell-proliferation. miRNAs regulating HK2 and MAP7 were identified, including hsa-mir-484 (HK2) and hsa-mir-17-5p, hsa-mir-93-5p, hsa-mir-106b-5p, among others (MAP7). Discussion: EGCG and myricetin, in combination, showed a synergistic effect on the ME180 cell line compared to the SiHa cell line. Conclusion: More in vitro and cell- and patient-derived xenograft models studies are needed to support the synergistic effect of EGCG and myricetin.
- 18 September 2025
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 25
Synergistic Antiproliferative Effects of EGCG and Myricetin on Cervical Cancer Biomarkers in ME180 and SiHa Cell Lines
Introduction: Identifying potential biomarkers for the detection, diagnosis, and monitoring of cervical cancer (CC) constitutes a key area for future research. Methods: Differentially expressed genes (DEGs) and survival-associated DEGs (SDEGs) were identified using the GEPIA2 database through the TCGA-CESC dataset. The 3D structures of target proteins were predicted using trRosetta and validated via SAVES v6.0. Phytocompounds were retrieved from the PubChem database, and docking studies were performed using AutoDock Vina. The miRNAs regulating HK2 and MAP7 were also predicted by implementing miRNetv2.0 and the CancerMIRNome database. Finally, the anticancer activity of these compounds was validated individually and in combination using the ME180 and SiHa CC cell lines. Results: The present study identified the top five most hazardous novel biomarkers through DEGs (5763) and SDEGs (500) (P-value ≤ 0.05). The phytocompounds EGCG and myricetin interacted with HK2 with binding affinities of -8.3 and -8.1 kcal/mol and RMSDs of 1.369Å and 1.452Å, respectively. Similarly, EGCG (-9.1 kcal/mol) and myricetin (-7.9 kcal/mol), with the RMSD of 1.682Å and 1.148Å, showed strong bonding with the MAP7. EGCG and myricetin treatment synergistically inhibited ME180 (IC50 = 63.49µM) and SiHa (IC50 = 81.54µM) cell-proliferation. miRNAs regulating HK2 and MAP7 were identified, including hsa-mir-484 (HK2) and hsa-mir-17-5p, hsa-mir-93-5p, hsa-mir-106b-5p, among others (MAP7). Discussion: EGCG and myricetin, in combination, showed a synergistic effect on the ME180 cell line compared to the SiHa cell line. Conclusion: More in vitro and cell- and patient-derived xenograft models studies are needed to support the synergistic effect of EGCG and myricetin.
- 1 April 2025
- Published by Bentham Science Publishers Ltd. in Protein & Peptide Letters
- Vol. 32 (4) , 280-298
Unveiling the Potential Role of Hesperetin and Emodin as a Combination Therapy to Inhibit the Pancreatic Cancer Progression against the C-Met Gene
Background: Pancreatic adenocarcinoma (PAAD) is one of the most prevalent cancers, and it has high death rates. Only 10% of PAAD patients can survive until 5 years. Hence, the improvement of survival rate of the patients should be improved. Aim: The present study used a computational approach to identify novel biomarkers and potentially effective small drug-like molecules in PAAD. Objective: The objective of this study was to identify the Differentially Expressed Genes (DEGs) and survival rate affecting genes (SDEGs) to single out the specific gene responsible for pancreatic cancer and predict the efficacy of interactions with hesperetin and emodin. Further, another objective was to validate the predicted efficacies using an MTT assay. Methods: The GEPIA2 database was used to analyze the TCGA-PAAD dataset and identify DEGs and SDEGs. Venn identified the commonly scattered genes between the DEGs and SDEGs. Network Analyst v3.0, CytoScape v3.10.1, and cytoHubba were used for PPI network construction and hub genes identification was described as target proteins. The PDB and PubChem were utilized to obtain the PDB structure of the target proteins and 13 phytocompounds in SDF format. Molecular docking studies were carried out and visualized by utilizing Autodock vina and Discovery Studio Visualizer v19.1.0.1828. The cytotoxicity was measured in the MiaPaCa-2 cell line after being treated with hesperetin and emodin. Results: A total of 9219 Differentially Expressed Genes (DEGs) from the TCGA-PAAD dataset were identified. Among them, 8740 and 479 genes were up and down-regulated with the statistical significance of P ≤ 0.05, respectively. Likely, 500 most survival rate affecting genes (SDEGs) in PAAD patients with a statistical significance of P ≤ 0.05 were identified. The common 137 genes were identified between these obtained DEGs and SDEGs. The survival heat map was delineated for the predicted 137 common genes. Ninety-six genes were identified as the most hazardous genes (highlighted in red). After that, the network was constructed by using protein-protein interaction (PPI) for the most hazardous 96 genes. From the constructed PPI network, the highly interacted top 10 genes were identified. The survival analysis was carried out to identify the most hazardous genes and revealed that all the identified genes significantly reduced the survival rate of the patients affected by PAAD. From that, high survival affecting 5 genes, such as CDK1, CENPE, NCAPG, KIF20A, and c-MET, were selected for further analysis. The molecular docking studies were carried out for the identified top 5 genes, with the 13 phytocompounds reviewed previously for anti-cancer activity. The molecular docking analysis revealed that the hesperetin (binding affinity (BA) = -8.0 kcal/mol; Root mean square deviation (RMSD) = 2.012 Å) and emodin (BA = -8.6 kcal/mol; RMSD = 1.605 Å) interacted well with the c-MET based on the number of hydrogen bonds and BA. Hence, the synergistic efficacy was validated in the cell line MiaPaCa-2 with the hesperetin, emodin, and hesperetin: emodin in combination and obtained the IC50 values of 171.3 μM, 72.94 μM, and 92.36 μM respectively. Conclusion: The results stated that emodin significantly reduced the cell proliferation rate of the MiaPaCa-2 pancreatic cells, and no synergistic effects were observed in this context with hesperetin. However, emodin improved the hesperetin efficacy in pancreatic cells, indicating that structural modification through pharmacokinetics by coupling these two compounds may help to identify novel compounds to treat pancreatic cancer in the future. However, further pancreatic cell lines, such as Panc-1, Bx- PC-3, etc., and in vivo models that include CDX and PDX are needed to verify the combination effect of hespertin and emodin on pancreatic cells.
- 1 April 2025
- Published by Bentham Science Publishers Ltd. in Protein & Peptide Letters
- Vol. 32 (4) , 280-298
Unveiling the Potential Role of Hesperetin and Emodin as a Combination Therapy to Inhibit the Pancreatic Cancer Progression against the C-Met Gene
Background: Pancreatic adenocarcinoma (PAAD) is one of the most prevalent cancers, and it has high death rates. Only 10% of PAAD patients can survive until 5 years. Hence, the improvement of survival rate of the patients should be improved. Aim: The present study used a computational approach to identify novel biomarkers and potentially effective small drug-like molecules in PAAD. Objective: The objective of this study was to identify the Differentially Expressed Genes (DEGs) and survival rate affecting genes (SDEGs) to single out the specific gene responsible for pancreatic cancer and predict the efficacy of interactions with hesperetin and emodin. Further, another objective was to validate the predicted efficacies using an MTT assay. Methods: The GEPIA2 database was used to analyze the TCGA-PAAD dataset and identify DEGs and SDEGs. Venn identified the commonly scattered genes between the DEGs and SDEGs. Network Analyst v3.0, CytoScape v3.10.1, and cytoHubba were used for PPI network construction and hub genes identification was described as target proteins. The PDB and PubChem were utilized to obtain the PDB structure of the target proteins and 13 phytocompounds in SDF format. Molecular docking studies were carried out and visualized by utilizing Autodock vina and Discovery Studio Visualizer v19.1.0.1828. The cytotoxicity was measured in the MiaPaCa-2 cell line after being treated with hesperetin and emodin. Results: A total of 9219 Differentially Expressed Genes (DEGs) from the TCGA-PAAD dataset were identified. Among them, 8740 and 479 genes were up and down-regulated with the statistical significance of P ≤ 0.05, respectively. Likely, 500 most survival rate affecting genes (SDEGs) in PAAD patients with a statistical significance of P ≤ 0.05 were identified. The common 137 genes were identified between these obtained DEGs and SDEGs. The survival heat map was delineated for the predicted 137 common genes. Ninety-six genes were identified as the most hazardous genes (highlighted in red). After that, the network was constructed by using protein-protein interaction (PPI) for the most hazardous 96 genes. From the constructed PPI network, the highly interacted top 10 genes were identified. The survival analysis was carried out to identify the most hazardous genes and revealed that all the identified genes significantly reduced the survival rate of the patients affected by PAAD. From that, high survival affecting 5 genes, such as CDK1, CENPE, NCAPG, KIF20A, and c-MET, were selected for further analysis. The molecular docking studies were carried out for the identified top 5 genes, with the 13 phytocompounds reviewed previously for anti-cancer activity. The molecular docking analysis revealed that the hesperetin (binding affinity (BA) = -8.0 kcal/mol; Root mean square deviation (RMSD) = 2.012 Å) and emodin (BA = -8.6 kcal/mol; RMSD = 1.605 Å) interacted well with the c-MET based on the number of hydrogen bonds and BA. Hence, the synergistic efficacy was validated in the cell line MiaPaCa-2 with the hesperetin, emodin, and hesperetin: emodin in combination and obtained the IC50 values of 171.3 μM, 72.94 μM, and 92.36 μM respectively. Conclusion: The results stated that emodin significantly reduced the cell proliferation rate of the MiaPaCa-2 pancreatic cells, and no synergistic effects were observed in this context with hesperetin. However, emodin improved the hesperetin efficacy in pancreatic cells, indicating that structural modification through pharmacokinetics by coupling these two compounds may help to identify novel compounds to treat pancreatic cancer in the future. However, further pancreatic cell lines, such as Panc-1, Bx- PC-3, etc., and in vivo models that include CDX and PDX are needed to verify the combination effect of hespertin and emodin on pancreatic cells.
- Open Access
- 3 March 2025
- Published by Manuscript Technomedia LLP in Indian Journal of Pharmaceutical Education and Research
- Vol. 59 (2) , 757-766
Chlorogenic Acid Functionalized Tin Oxide-Sodium Alginate Hybrid Nanomaterials Induce Oxidative Stress-Mediated Apoptosis in Breast Cancer MDA-MB-231 Cells
Background Nanotechnology has emerged as a novel research area to address the several problems associated with existing cancer treatments. Objectives The present work was focused on synthesizing and characterizing the tin oxide-sodium alginate-chlorogenic acid hybrid nanomaterials (SnO2-SA-CA HNMs) for enhanced anticancer effects against breast cancer MDA-MB-231 cells. Materials and Methods The synthesized SnO2-SA-CA HNMs were characterized using several methods, including UV-vis spectroscopy, X-ray Diffraction (XRD), Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM), Energy Dispersive X-ray (EDX), Fourier Transform Infrared (FT-IR), Dynamic Light Scattering (DLS) and Photoluminescence (PL) analyses. The MTT assay was done to assess the cytotoxicity of SnO2-SA-CA HNMs against MDA-MB-231 cells. The apoptotic cell death was analyzed by the dual staining assay. The oxidative stress parameter levels were analyzed using corresponding assay kits. Results The results of the different characterization studies are confirmed the formation of metallic SnO2-SA-CA HNMs with an average size of 93 nm. The SnO2-SA-CA HNMs have a crystalline nature, clustered morphology and cuboidal structures. The existence of various functional groups and elements in the HNMs was also confirmed by the FT-IR and DLS analyses, respectively. The SnO2-SA-CA HNMs have demonstrated a substantial effect on inhibiting the viability of MDA-MB-231 cells. The dual staining result also proved the onset of apoptotic cell death in the HNMs-treated cells. The HNMs treatment effectively decreased the antioxidant level, thereby promoting oxidative stress. Conclusion The present findings suggest that SnO2-SA-CA HNMs exhibit potential as a potential therapeutic candidate to treat breast cancer.
- 3 March 2025
- Published by Manuscript Technomedia LLP in Indian Journal of Pharmaceutical Education and Research
- Vol. 59 (2) , 757-766
Open AccessChlorogenic Acid Functionalized Tin Oxide-Sodium Alginate Hybrid Nanomaterials Induce Oxidative Stress-Mediated Apoptosis in Breast Cancer MDA-MB-231 Cells
Background Nanotechnology has emerged as a novel research area to address the several problems associated with existing cancer treatments. Objectives The present work was focused on synthesizing and characterizing the tin oxide-sodium alginate-chlorogenic acid hybrid nanomaterials (SnO2-SA-CA HNMs) for enhanced anticancer effects against breast cancer MDA-MB-231 cells. Materials and Methods The synthesized SnO2-SA-CA HNMs were characterized using several methods, including UV-vis spectroscopy, X-ray Diffraction (XRD), Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM), Energy Dispersive X-ray (EDX), Fourier Transform Infrared (FT-IR), Dynamic Light Scattering (DLS) and Photoluminescence (PL) analyses. The MTT assay was done to assess the cytotoxicity of SnO2-SA-CA HNMs against MDA-MB-231 cells. The apoptotic cell death was analyzed by the dual staining assay. The oxidative stress parameter levels were analyzed using corresponding assay kits. Results The results of the different characterization studies are confirmed the formation of metallic SnO2-SA-CA HNMs with an average size of 93 nm. The SnO2-SA-CA HNMs have a crystalline nature, clustered morphology and cuboidal structures. The existence of various functional groups and elements in the HNMs was also confirmed by the FT-IR and DLS analyses, respectively. The SnO2-SA-CA HNMs have demonstrated a substantial effect on inhibiting the viability of MDA-MB-231 cells. The dual staining result also proved the onset of apoptotic cell death in the HNMs-treated cells. The HNMs treatment effectively decreased the antioxidant level, thereby promoting oxidative stress. Conclusion The present findings suggest that SnO2-SA-CA HNMs exhibit potential as a potential therapeutic candidate to treat breast cancer.
- 1 February 2025
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 25 (2) , 183-203
Screening miRNAs to Hinder the Tumorigenesis of Renal Clear Cell Carcinoma Associated with KDR Expression
Introduction: This study delved into the role of Kinase Insert Domain Receptor (KDR) and its associated miRNAs in renal cell carcinoma through an extensive computational analysis. The potential of our findings to guide future research in this area is significant. Methods: Our methods, which included the use of UALCAN and GEPIA2 databases, as well as miRDB, MirDIP, miRNet v2.0, miRTargetLink, MiEAA v2.1, TarBase v8.0, INTERNET, and miRTarBass, were instrumental in identifying the regulation of miRNA associated with KDR expression. The predicted miRNA was validated with the TCGA-KIRC patients’ samples by implementing CancerMIRNome. The TargetScanHuman v8.0 was implemented to identify the associations between human miRNAs and KDR. A Patch Dock server analyzed the interactions between hsa-miR-200b-3p-KDR and hsa-miR-200b-3p with KDR. Results: The KDR expression rate was investigated in the Kidney Renal Cell Carcinoma (KIRC) samples, and adjacent normal tissues revealed that the expression rate was significantly higher than the normal samples, which was evident from the strong statistical significance (P = 1.63e-12). Likely, the KDR ex-pression rate was estimated as high at tumor grade 1 and gradually decreased till the metastasis grade, reducing the survival rate of the KIRC patients. To identify these signals early, we predicted a miRNA that could trigger the expression of KDR. Furthermore, we uncovered the potential associations between miR-200c-3p expressions by regulating KDR towards the progression of KIRC. Discussion: Upon examining the outcome, it became evident that miR-200c-3p was significantly down-regulated in KIRC compared to the normal samples. Moreover, the negative correlation was obtained for hsa-miR-200c-3p (R = - 0.276) along with the KDR expression describing that the increased rate of hsa-miR-200c-3p might reduce the KDR expression rate, which may suppress the KIRC initiation or progres-sion. Conclusion: The in-silico analysis indicated that the significant increase in KDR expression during the initiation of KIRC could serve as an early diagnostic marker. Moreover, KDR could be utilized to identify advancements in KIRC stages. Additionally, hsa-miR-200c-3p was identified as a potential regulator capable of downregulating and upregulating KDR expression among the 24 miRNAs screened. This find-ing holds promise for future research endeavors. Concurrent administration of the FDA-approved 5-fluor-ouracil with KIRC drugs, such as sorafenib, zidovudine, and everolimus, may have the potential to en-hance the therapeutic efficacy in downregulating hsa-miR-200c-3p. However, further in vitro studies are imperative to validate these findings and gain a comprehensive understanding of the intricate regulatory interplay involving hsa-miR-200c-3p, KDR, 5-fluorouracil, and other FDA-approved drugs for the treat-ment of KIRC. This will facilitate the identification of KIRC stage progression and its underlying pre-ventative mechanisms.
- 1 February 2025
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 25 (2) , 183-203
Screening miRNAs to Hinder the Tumorigenesis of Renal Clear Cell Carcinoma Associated with KDR Expression
Introduction: This study delved into the role of Kinase Insert Domain Receptor (KDR) and its associated miRNAs in renal cell carcinoma through an extensive computational analysis. The potential of our findings to guide future research in this area is significant. Methods: Our methods, which included the use of UALCAN and GEPIA2 databases, as well as miRDB, MirDIP, miRNet v2.0, miRTargetLink, MiEAA v2.1, TarBase v8.0, INTERNET, and miRTarBass, were instrumental in identifying the regulation of miRNA associated with KDR expression. The predicted miRNA was validated with the TCGA-KIRC patients’ samples by implementing CancerMIRNome. The TargetScanHuman v8.0 was implemented to identify the associations between human miRNAs and KDR. A Patch Dock server analyzed the interactions between hsa-miR-200b-3p-KDR and hsa-miR-200b-3p with KDR. Results: The KDR expression rate was investigated in the Kidney Renal Cell Carcinoma (KIRC) samples, and adjacent normal tissues revealed that the expression rate was significantly higher than the normal samples, which was evident from the strong statistical significance (P = 1.63e-12). Likely, the KDR ex-pression rate was estimated as high at tumor grade 1 and gradually decreased till the metastasis grade, reducing the survival rate of the KIRC patients. To identify these signals early, we predicted a miRNA that could trigger the expression of KDR. Furthermore, we uncovered the potential associations between miR-200c-3p expressions by regulating KDR towards the progression of KIRC. Discussion: Upon examining the outcome, it became evident that miR-200c-3p was significantly down-regulated in KIRC compared to the normal samples. Moreover, the negative correlation was obtained for hsa-miR-200c-3p (R = - 0.276) along with the KDR expression describing that the increased rate of hsa-miR-200c-3p might reduce the KDR expression rate, which may suppress the KIRC initiation or progres-sion. Conclusion: The in-silico analysis indicated that the significant increase in KDR expression during the initiation of KIRC could serve as an early diagnostic marker. Moreover, KDR could be utilized to identify advancements in KIRC stages. Additionally, hsa-miR-200c-3p was identified as a potential regulator capable of downregulating and upregulating KDR expression among the 24 miRNAs screened. This find-ing holds promise for future research endeavors. Concurrent administration of the FDA-approved 5-fluor-ouracil with KIRC drugs, such as sorafenib, zidovudine, and everolimus, may have the potential to en-hance the therapeutic efficacy in downregulating hsa-miR-200c-3p. However, further in vitro studies are imperative to validate these findings and gain a comprehensive understanding of the intricate regulatory interplay involving hsa-miR-200c-3p, KDR, 5-fluorouracil, and other FDA-approved drugs for the treat-ment of KIRC. This will facilitate the identification of KIRC stage progression and its underlying pre-ventative mechanisms.
- 3 November 2023
- Published by Elsevier
- p. 207-226
Pancreatic cancer stem cells and inflammation: milestones achieved and challenges ahead
- 3 November 2023
- Published by Elsevier
- p. 207-226
Pancreatic cancer stem cells and inflammation: milestones achieved and challenges ahead